Cargando…

Patient attitudes and understanding about biosimilars: an international cross-sectional survey

OBJECTIVE: To understand the levels of awareness, usage, and knowledge of biosimilars among patients, caregivers, and the general population in the US and the European Union; perceptions of biosimilars compared to originator biologics; perceived benefits and drawbacks of clinical trials; and whether...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jacobs, Ira, Singh, Ena, Sewell, K Lea, AL-Sabbagh, Ahmad, Shane, Lesley G
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2016
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4889091/ https://www.ncbi.nlm.nih.gov/pubmed/27307714 http://dx.doi.org/10.2147/PPA.S104891

Ejemplares similares

Biosimilars for the Treatment of Chronic Inflammatory Diseases: A Systematic Review of Published Evidence
por: Jacobs, Ira, et al.
Publicado: (2016)

Drug tendering: drug supply and shortage implications for the uptake of biosimilars
por: Dranitsaris, George, et al.
Publicado: (2017)

Assessing the Value of Biosimilars: A Review of the Role of Budget Impact Analysis
por: Simoens, Steven, et al.
Publicado: (2017)

Clinical and regulatory perspectives on biosimilar therapies and intended copies of biologics in rheumatology
por: Mysler, Eduardo, et al.
Publicado: (2016)

An online survey among US patients with immune-mediated conditions: Attitudes about biosimilars
por: Gibofsky, Allan, et al.
Publicado: (2023)

Biosimilars Have Arrived: Rituximab
por: Greenwald, Maria, et al.
Publicado: (2018)

A practical guide about biosimilar data for health care providers treating inflammatory diseases
por: Markenson, Joseph, et al.
Publicado: (2017)

Monoclonal Antibody and Fusion Protein Biosimilars Across Therapeutic Areas: A Systematic Review of Published Evidence
por: Jacobs, Ira, et al.
Publicado: (2016)

Statistical Primer on Biosimilar Clinical Development
por: Isakov, Leah, et al.
Publicado: (2016)

Biosimilars and the extrapolation of indications for inflammatory conditions
por: Tesser, John RP, et al.
Publicado: (2017)

US rheumatologists’ beliefs and knowledge about biosimilars: a survey
por: Gibofsky, Allan, et al.
Publicado: (2020)

Barriers to the Access of Bevacizumab in Patients with Solid Tumors and the Potential Impact of Biosimilars: A Physician Survey
por: Monk, Bradley J., et al.
Publicado: (2017)

Regulatory considerations in oncologic biosimilar drug development
por: Macdonald, Judith C, et al.
Publicado: (2015)

The Language of Biosimilars: Clarification, Definitions, and Regulatory Aspects
por: Declerck, Paul, et al.
Publicado: (2017)

Clinical considerations for the development of biosimilars in oncology
por: Socinski, Mark A, et al.
Publicado: (2015)

Biosimilar Drugs for Psoriasis: Principles, Present, and Near Future
por: Carrascosa, Jose-Manuel, et al.
Publicado: (2018)

There Is No Substitute for Effective Education About Biosimilars
por: Maltz, Ross M, et al.
Publicado: (2021)

Biosimilars for the Treatment of Cancer: A Systematic Review of Published Evidence
por: Jacobs, Ira, et al.
Publicado: (2017)

Bevacizumab in Colorectal Cancer: Current Role in Treatment and the Potential of Biosimilars
por: Rosen, Lee S., et al.
Publicado: (2017)

Review and results of a survey about biosimilars prescription and challenges in the Middle East and North Africa region
por: Farhat, Fadi, et al.
Publicado: (2016)

Development of biosimilars in an era of oncologic drug shortages
por: Li, Edward, et al.
Publicado: (2015)

Barriers to the Use of Trastuzumab for HER2+ Breast Cancer and the Potential Impact of Biosimilars: A Physician Survey in the United States and Emerging Markets
por: Lammers, Philip, et al.
Publicado: (2014)

Rituximab in the treatment of follicular lymphoma: the future of biosimilars in the evolving therapeutic landscape
por: Subramanian, Janakiraman, et al.
Publicado: (2017)

Biosimilars in rheumatology: understanding the rigor of their development
por: Goel, Niti, et al.
Publicado: (2017)

Will bevacizumab biosimilars impact the value of systemic therapy in gynecologic cancers?
por: Monk, Bradley J., et al.
Publicado: (2017)

Can biosimilars help achieve the goals of US health care reform?
por: Boccia, Ralph, et al.
Publicado: (2017)

European Stakeholder Learnings Regarding Biosimilars: Part I—Improving Biosimilar Understanding and Adoption
por: Barbier, Liese, et al.
Publicado: (2020)

How Similar Are Biosimilars? What Do Clinicians Need to Know About Biosimilar and Follow-On Insulins?
por: Triplitt, Curtis, et al.
Publicado: (2017)

Assessing Knowledge and Attitude of Healthcare Professionals on Biosimilars: A National Survey for Pharmacists and Physicians in Taiwan
por: Poon, Samantha Yun-Kai, et al.
Publicado: (2021)

Potential of Biosimilars to Increase Access to Biologics: Considerations for Advanced Practice Providers in Oncology
por: Tinsley, Sara M., et al.
Publicado: (2018)

Attitudes of Australians with inflammatory arthritis to biologic therapy and biosimilars
por: Quinlivan, Alannah, et al.
Publicado: (2022)

Evolving landscape of human epidermal growth factor receptor 2-positive breast cancer treatment and the future of biosimilars
por: Jackisch, Christian, et al.
Publicado: (2017)

Evaluating imbalances of adverse events during biosimilar development
por: Vana, Alicia M., et al.
Publicado: (2016)

Awareness and Knowledge of Pharmacists toward Biosimilar Medicines: A Survey in Jordan
por: Oqal, Muna, et al.
Publicado: (2022)

Cross-sectional survey of attitudes and beliefs about back pain in New Zealand
por: Darlow, Ben, et al.
Publicado: (2014)

Knowledge and attitude of Lebanese women about cosmetics: a cross-sectional survey
por: Chahine, Bahia, et al.
Publicado: (2023)

Proposal of International Council for Harmonization (ICH) Guideline for the Approval of Biosimilars
por: Niazi, Sarfaraz K., et al.
Publicado: (2022)

Nurses’ Knowledge and Attitudes towards Biosimilar Medicines as Part of Evidence-Based Nursing Practice—International Pilot Study within the Project Biosimilars Nurses Guide Version 2.0
por: Friganović, Adriano, et al.
Publicado: (2022)

What do oncologists need to know about biosimilar products?
por: Leung, Linda K. S., et al.
Publicado: (2016)

Improving the understanding of originator and biosimilar biologics among healthcare providers in Saudi Arabia
por: Omair, Mohammed A., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_b2vreut2g1h2ehca9scq872f3t